tetano
Editor, Senior Moderator
Drug Metab Pharmacokinet. 2013 Apr 9. [Epub ahead of print]
Population Pharmacokinetics of Laninamivir and Its Prodrug Laninamivir Octanoate in Healthy Subjects, and Adult and Pediatric Patients with Influenza Virus Infection.
Yoshihara K, Ishizuka H, Kubo Y.
Source
Translational Medicine and Clinical Pharmacology Department, Daiichi Sankyo Company, Ltd.
Abstract
Laninamivir octanoate (LO) is a new neuraminidase inhibitor for inhalation. The objectives of this study were to model the population pharmacokinetics of LO and its active metabolite laninamivir after inhaled administration of LO using pooled population of healthy subjects, and adult and pediatric patients with influenza virus infection from 8 clinical studies, and to evaluate covariate effects on pharmacokinetics. The pharmacokinetics of LO and laninamivir in plasma and urine were well-described by the structural models that consist of a 2-compartment model for LO with instantaneous bolus input and first-order elimination; and a 1-compartment model for laninamivir with formation of laninamivir via the metabolic pathway from LO in systemic circulation, entry of laninamivir from the respiratory tract compartment, and linear elimination. Creatinine clearance was identified as a covariate of apparent total clearance for LO and renal clearances for LO and laninamivir, with the largest effect on laninamivir exposure. Body weight was identified to affect distribution volumes of LO and laninamivir and metabolic clearance of LO, however had no notable effect on their exposures across a wide body weight range evaluated. The population pharmacokinetic model also provides insight into the likely kinetics of drug disposition in the respiratory tract following inhaled administration.
PMID:
23574886
[PubMed - as supplied by publisher]
Free full text
http://www.ncbi.nlm.nih.gov/pubmed/23574886
Population Pharmacokinetics of Laninamivir and Its Prodrug Laninamivir Octanoate in Healthy Subjects, and Adult and Pediatric Patients with Influenza Virus Infection.
Yoshihara K, Ishizuka H, Kubo Y.
Source
Translational Medicine and Clinical Pharmacology Department, Daiichi Sankyo Company, Ltd.
Abstract
Laninamivir octanoate (LO) is a new neuraminidase inhibitor for inhalation. The objectives of this study were to model the population pharmacokinetics of LO and its active metabolite laninamivir after inhaled administration of LO using pooled population of healthy subjects, and adult and pediatric patients with influenza virus infection from 8 clinical studies, and to evaluate covariate effects on pharmacokinetics. The pharmacokinetics of LO and laninamivir in plasma and urine were well-described by the structural models that consist of a 2-compartment model for LO with instantaneous bolus input and first-order elimination; and a 1-compartment model for laninamivir with formation of laninamivir via the metabolic pathway from LO in systemic circulation, entry of laninamivir from the respiratory tract compartment, and linear elimination. Creatinine clearance was identified as a covariate of apparent total clearance for LO and renal clearances for LO and laninamivir, with the largest effect on laninamivir exposure. Body weight was identified to affect distribution volumes of LO and laninamivir and metabolic clearance of LO, however had no notable effect on their exposures across a wide body weight range evaluated. The population pharmacokinetic model also provides insight into the likely kinetics of drug disposition in the respiratory tract following inhaled administration.
PMID:
23574886
[PubMed - as supplied by publisher]
Free full text
http://www.ncbi.nlm.nih.gov/pubmed/23574886